Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients
BERGEN, Norway, June 11, 2021 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting
Share this article
More News
3 Growth Stocks to Stash
June 9, 2026
IBM Stock Analysis: Buy or Sell?
June 9, 2026
What’s Behind The Price Momentum?
June 9, 2026